Latest news with #NPCE
Business Insider
25-06-2025
- Business
- Business Insider
NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed
NeuroPace (NPCE) announced the appointment of Patrick Williams as CFO, effective June 20. Rebecca Kuhn has entered into an agreement with the company to depart from her CFO role and serve in an advisory role to the company for a twelve-month period. Williams most recently served as CFO at STAAR Surgical (STAA). Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yahoo
29-05-2025
- Business
- Yahoo
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating
On May 28, H.C. Wainwright analyst Yi Chen initiated coverage of NeuroPace, Inc. (NASDAQ:NPCE) with a Buy rating and a price target of $18. The rating comes after the company released preliminary results for one-year data in NAUTILUS study. On May 27, the company announced key results from its NAUTILUS study, the first clinical trial evaluating its RNS system for drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint at 12 weeks post-implant, demonstrating a low rate of serious adverse events and reinforcing the device's established safety profile. The analyst noted that the system demonstrated significant seizure reduction in the clinical stage. A close-up of a medical device being calibrated and tested in a clinical laboratory setting. Moreover, NeuroPace, Inc. (NASDAQ:NPCE) delivered robust results for the fiscal first quarter of 2025. The revenue grew more than 24% year-over-year to $22.52 million and surpassed expectations by $676,490, whereas the EPS of $-0.21 also exceeded consensus by $0.03. The analyst said that the stock has appreciated over 150% during the past year and the recent data from the study presents an attractive entry point for investors. NeuroPace Inc. (NASDAQ:NPCE) is a commercial-stage medical device company that develops the RNS system. RNS system is an implantable brain-responsive device designed to reduce or prevent seizures in people with drug-resistant epilepsy. While we acknowledge the potential of NPCE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NPCE and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
NeuroPace Inc.: Q1 Earnings Snapshot
MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — NeuroPace Inc. (NPCE) on Tuesday reported a loss of $6.6 million in its first quarter. The Mountain View, California-based company said it had a loss of 21 cents per share. The company posted revenue of $22.5 million in the period. NeuroPace Inc. expects full-year revenue in the range of $93 million to $97 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on NPCE at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
NeuroPace Inc.: Q1 Earnings Snapshot
MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — NeuroPace Inc. (NPCE) on Tuesday reported a loss of $6.6 million in its first quarter. The Mountain View, California-based company said it had a loss of 21 cents per share. The company posted revenue of $22.5 million in the period. NeuroPace Inc. expects full-year revenue in the range of $93 million to $97 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on NPCE at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
